Healthcare Beyond H.R. 1: What is the alternative?

Healthcare policy is unusually prone to slogans. "Repeal Obamacare." "Protect Medicaid." "Lower costs." "Protect patients with pre-existing conditions." Each names an objective. None of them, by itself, is a way to get people covered. That distinction runs through this page. Huizenga's record includes real healthcare work, some of it bipartisan and some of it now law, and that work is laid out below in full. The question is whether those pieces add up to a framework on the scale of the coverage mechanisms he has voted to repeal, reduce, or let expire. The ACA was signed in March 2010, so the law is now more than sixteen years old, and "what comes instead" is no longer a hypothetical question.

Two things this page doesn't show, because reliable district-level figures weren't found: Marketplace enrollment for MI-4 specifically, and a count of hospitals or rural providers inside the district's lines. Statewide, the Michigan Department of Health and Human Services (MDHHS) is preparing Healthy Michigan Plan members for H.R. 1's work requirements, which begin in January 2027 for certain members aged 19–64, and for a move from annual to six-month eligibility renewals for most members (MDHHS, July 23, 2026).

These are the healthcare-coverage votes reviewed for this page, oldest first. Every vote and total was checked against the House Clerk's record, and each bill's furthest stage against its GovInfo bill-status file. The Voting Record page covers his votes on other subjects.

Opposition, and what he said should replace it

Huizenga's opposition to the ACA predates his first vote on it. In March 2012 his office said he had "voted 26 times to repeal, defund, or dismantle the health care law in its entirety or some of its worst provisions" (Huizenga press release, Mar. 23, 2012). He voted for full repeal in 2011 and again in July 2012. In January 2016 he voted to send President Obama a reconciliation bill repealing major parts of the law, which the President vetoed. In May 2017 he voted for the American Health Care Act. His current issues page still says he "believes that Obamacare has failed the American people and our economy" (Huizenga, Health Care issue page).

He has also said what he wanted instead, in general terms. In 2012 he called for "a bipartisan step-by-step approach that puts the patients and their doctors, not Washington, in charge of their health decisions" (July 11, 2012). After the 2017 vote he called the AHCA "the beginning, not the end of the journey to fix our nation's broken healthcare system," and said it restored the freedom to choose a plan, "not what Washington dictates they must have" (May 4, 2017). His issues page lists the elements he supports: "curbing costly junk lawsuits, encouraging the use of health savings accounts, and empowering small business and states to use innovative means to reduce health care costs," plus protections for people with pre-existing conditions.

The AHCA is the one time the record shows him voting for a comprehensive replacement, so it deserves the same treatment as the votes that came later. It had its own coverage mechanism: age-based tax credits in place of the ACA's income-based subsidies, a Patient and State Stability Fund, and state waivers. In May 2017 CBO estimated that the House-passed bill would reduce deficits by $119 billion over 2017–2026 and increase the number of uninsured people by 23 million in 2026, relative to then-current law. Huizenga's statement on that estimate emphasized CBO's projections of lower premiums and deficits (May 24, 2017). The bill failed in the Senate that July. The record reviewed for this page did not identify another comprehensive replacement he has voted for or sponsored since.

The affordability question

The ACA's premium tax credit helps people who buy coverage through the Marketplaces. The American Rescue Plan Act of 2021 made the credit larger, and the 2022 reconciliation law (the Inflation Reduction Act) extended the larger version through 2025. The enhanced version did two things: it lowered the share of income eligible households were expected to pay toward a benchmark plan, and it extended help to households above the ACA's original cutoff of 400% of the poverty line.

It also costs federal money, and that belongs in the same paragraph. In September 2025 CBO estimated that making the enhanced credits permanent would increase deficits by $350 billion over 2026–2035 and increase the number of people with health insurance by 3.8 million in 2035. Congress didn't extend them, and they expired at the end of 2025. CBO's July 2026 report projects that average monthly Marketplace enrollment falls from 22 million in 2025 to 17 million in 2026, reflecting both the credits' expiration and the 2025 reconciliation law, and CBO notes that it can't cleanly separate those effects. CBO also reports that the average benchmark premium rose sharply in 2026, "largely driven by the disproportionate disenrollment of healthier marketplace enrollees after the expiration of the expanded premium tax credit," along with higher-than-expected claims costs and insurer uncertainty.

H.R. 1834 carries the title "Breaking the Gridlock Act," left over from an earlier, broader version of the bill. The version the House passed contained one section: it extended the enhanced premium-tax-credit rules, including eligibility above 400% of poverty, through 2028. It reached the floor through a Democratic discharge petition, which the House adopted on Jan. 7 (Roll 4, 221–205). On Jan. 8 it passed 230–196, with all 213 Democrats who voted and 17 Republicans voting yes. Huizenga voted no, as he did on the discharge motion and the rule. The Senate placed it on its calendar on Feb. 10, 2026, and it hasn't moved since, according to Congress's bill-status data.

CBO estimated that the bill would increase deficits by $80.6 billion over 2026–2035 and increase the number of people with health insurance by 4.0 million in 2028, the last full year of the extension. It also estimated that gross benchmark premiums would be 9.0% lower in 2028 than under current law, because healthier people would stay enrolled. On the day of the vote, Huizenga told the Detroit News: "We have not rooted out the waste, fraud and abuse, which we are seeing in spades." He called "this rush to just throw money at a problem without fixing the root cause of the problem" "just foolish, in my mind." He said he would look at a Senate compromise, while noting that only a small share of Americans use the Marketplaces (Detroit News, Jan. 8, 2026). He made a similar argument on Fox Business in December 2025 (network summary, secondary). His explanation doesn't address CBO's estimates of the extension's coverage or premium effects.

There are substantive reasons to oppose the extension, and they belong here. It adds to deficits at a time when the national debt has passed $40 trillion. Critics argue that larger premium subsidies pay for high prices rather than lowering them, and that they shield enrollees and insurers from the full cost of coverage. Letting a subsidy lapse doesn't make care itself cheaper, though. It changes who pays. For households that lost some or all of the enhanced credit, more of the premium moved from the federal government to the enrollee.

Three weeks before the H.R. 1834 vote, Huizenga voted for the House Republican alternative. The Lower Health Care Premiums for All Americans Act (H.R. 6703) passed 216–211 on Dec. 17, 2025. It didn't extend the enhanced credits. Instead it would expand association health plans, codify employer-funded accounts that workers can use to buy individual coverage, require pharmacy benefit managers to disclose rebates and costs to employer plans, and appropriate money for the ACA's cost-sharing reductions, available only to plans that limit abortion coverage to cases of rape, incest, or danger to the mother's life. Huizenga is also an original cosponsor of the stand-alone Association Health Plans Act (H.R. 2528), which the Education and Workforce Committee reported in December 2025.

This is the most direct evidence of what Huizenga supports on affordability, and CBO's estimate shows both what it does and what it doesn't. CBO and JCT estimated that it would reduce deficits by $35.6 billion over 2026–2035 and lower gross benchmark premiums by 11%, on average, through 2035. They also estimated that it would reduce the number of people with health insurance by an average of 100,000 a year over 2027–2035. The two findings come from the same mechanism. Funding cost-sharing reductions ends "silver loading," the practice that lets insurers raise silver-plan premiums and, with them, the tax credit. CBO estimated that this would reduce premium tax credits by $131.1 billion, and that enrollment would fall mainly among people between 200% and 400% of poverty, whose credit would then cover a smaller share of non-silver plans. Lower gross premiums, in other words, don't mean lower net premiums for every subsidized enrollee. The association-plan section would move about 700,000 people a year into association plans, about 200,000 of whom would otherwise be uninsured. The House passed the bill, and the Senate hasn't acted on it. The record reviewed for this page did not identify a Huizenga statement on it.

Huizenga voted for H.R. 1 on final passage on July 3, 2025. His office said the law "makes significant progress to eliminate waste, fraud, and abuse from both SNAP and Medicaid by implementing work requirements for able-bodied individuals," and that the changes "will preserve these important safety net programs for those who need it most — namely, low-income mothers, children, the elderly, and disabled Americans" (Huizenga press release, July 3, 2025). That's his description of what the law does. The projected effects come from CBO.

For the enacted law, CBO estimated that its health provisions would increase the number of uninsured people by 10.0 million in 2034, relative to CBO's January 2025 baseline. Of that, 7.5 million comes from the Medicaid policies, 2.1 million from the Marketplace policies, and the remainder from Medicare policies and interactions among them (CBO, Aug. 11, 2025, supplemental data). The work requirement alone accounts for 5.3 million of the increase in 2034. CBO expects most enrollees subject to it to meet it or qualify for an exemption, and projects that about 2.9 million will lose coverage for not meeting it and about 2.8 million more because of the added paperwork (CBO, Oct. 28, 2025). CBO's broader July 2026 baseline projects the uninsured population rising from 30 million in 2026 to 37 million in 2036, "largely because of provisions of the 2025 reconciliation act." That baseline also reflects the expired enhanced credits and other factors, so it isn't a separate estimate that can be added to the 10.0 million. All of these are projections, and CBO describes them as uncertain. The district-level provisions are covered in the H.R. 1 district-impact piece.

Huizenga can reasonably argue that Medicaid should be targeted more tightly and that working-age adults without disabilities should work, study, or volunteer as a condition of coverage. Those are defensible objectives. They also have measurable coverage consequences, and both belong on the same page.

The pieces of an alternative

It would be inaccurate to say Huizenga has done nothing on healthcare. A search of his sponsored and cosponsored legislation across all his terms, his office's releases, and the votes above turned up the following. Some of it became law.

This is substantive work. The mental-health and pediatric-cancer bills, the PBM and transparency votes, and the multi-share coverage idea address real problems, and several are bipartisan. The multi-share bill is the one item aimed directly at coverage for people who can't afford it. It's also West Michigan-grown, and it's aimed at exactly the population that H.R. 1's work requirements affect: low-income workers moving off Medicaid.

Washington and medical decisions

Huizenga has argued for years that health decisions should move away from Washington. In 2012 he said patients and their doctors, "not Washington," should be "in charge of their health decisions." In 2016 he said it was "far past time to take power away from bureaucrats and put the focus back on patients" (Jan. 6, 2016). In 2017 he called for moving "away from the Washington knows best mentality." Recent federal policy in two areas of medicine raises the question of how that principle applies when Washington acts through Medicare and Medicaid. The two areas involve different statutes and different legal disputes, so they're taken separately below.

They're on this page partly because of the Congressional Responsibility test. Congress writes the Medicare and Medicaid statutes that CMS relies on, appropriates the money, oversees the agencies, and decides how far federal healthcare authority reaches. That doesn't mean Congress should manage clinical practice. It means that when an agency uses those statutes in a new way, whether it's authorized to do so is a question for Congress too.

On Dec. 19, 2025, CMS published two proposed rules. They work through different levers, and they're at different stages.

• Federal Medicaid and CHIP funding (final). The final rule, published Aug. 13, 2026 and effective Oct. 13, 2026, bars federal Medicaid funding for what the rule calls "sex-rejecting procedures" (puberty blockers, cross-sex hormones, and surgeries) for people under 18, and federal CHIP funding for people under 19. States may keep claiming federal funds for up to six months for young people already on hormone therapy. The rule says it doesn't stop states from paying for these services with state-only funds, or private insurers from covering them. It cites the Medicaid statute's economy, efficiency, and quality-of-care provisions (sections 1902(a)(19) and 1902(a)(30)(A) of the Social Security Act) as its authority.
• Hospital participation in Medicare and Medicaid (proposed). The proposed condition of participation would prohibit any Medicare-participating hospital from performing these procedures on anyone under 18, regardless of who pays. This lever reaches further than the funding rule: it's about whether a hospital may provide the care at all while staying in Medicare and Medicaid, not whether federal money pays for it. Comments closed Feb. 17, 2026. No final rule had been published in the Federal Register as of this review.

The administration's rationale, as stated in the rules, is that the current evidence doesn't support a favorable risk-benefit profile for these treatments in minors, and that the potential for irreversible harm is significant. Supporters argue that the federal government shouldn't pay for, or let participating hospitals provide, interventions they consider experimental. Opponents argue that the government is substituting a federal policy judgment for decisions that belong to patients, parents, physicians, professional standards, and state regulation of medicine. Michigan's attorney general joined a coalition of 22 states suing over the final funding rule in early September. According to Attorney General Dana Nessel's office, the states argue that CMS lacks statutory authority, and that the rule violates the Administrative Procedure Act and the Spending Clause. Those are one party's claims in pending litigation. As of this review, no court order blocking the rule had been found, and the Oct. 13 effective date stands. Separately, the final rule itself notes that a federal court in Oregon vacated a December 2025 declaration by the HHS Secretary on these treatments, holding that the Secretary lacked statutory authority to issue it.

On the underlying policy, Huizenga's position is on the record through his votes. In December 2025 he voted for the Do No Harm in Medicaid Act (H.R. 498), which would write a ban on federal Medicaid funding for these procedures for minors into statute, and for the Protect Children's Innocence Act (H.R. 3492), which would make performing them on minors a federal crime. Both passed the House, and neither has had Senate action. The record reviewed for this page didn't identify a statement from him on either vote.

The institutional question is narrower, and it's still open. H.R. 498 is Congress legislating, and Congress setting Medicaid's terms by statute is squarely within its role. The proposed hospital condition of participation is the executive branch using Medicare participation to decide which treatments hospitals may provide at all. Huizenga has taken a position on that kind of lever before. In 2021 he opposed a CMS rule requiring COVID-19 vaccination of staff at facilities participating in Medicare and Medicaid, calling it a "coercive" mandate, and he supported using the Congressional Review Act to overturn it as "an important check on the Biden Administration's executive overreach" (Dec. 10, 2021; Jan. 13, 2022). The two rules differ in subject and in their stated health rationales. The record reviewed for this page did not identify a public Huizenga position on the proposed hospital condition of participation, or on whether CMS has the authority to impose it. Silence doesn't establish agreement. It leaves his position on that question unknown.

The Emergency Medical Treatment and Labor Act (42 U.S.C. 1395dd) requires Medicare-participating hospitals with emergency departments to screen anyone who comes in and, if they have an emergency medical condition, to stabilize them or arrange an appropriate transfer. After Dobbs, CMS issued guidance in July 2022 (QSO-22-22-Hospitals) saying that if a physician determines that abortion is the stabilizing treatment a pregnant patient's emergency condition requires, EMTALA requires the hospital to provide it, and that the federal requirement preempts a conflicting state law.

That reading was contested in court and never settled. The Fifth Circuit held that the guidance likely exceeded the statute and upheld an injunction barring its enforcement against Texas and members of two medical associations (Texas v. Becerra, Jan. 2024), and the Supreme Court declined review in October 2024 (No. 23-1076). In the Idaho case, the Supreme Court dismissed the appeal as improvidently granted in June 2024 without deciding the question (Moyle v. United States). On May 29, 2025, CMS rescinded the 2022 guidance. It said it will continue to enforce EMTALA's screening and stabilization requirements, "including for identified emergency medical conditions that place the health of a pregnant woman or her unborn child in serious jeopardy." The statute itself didn't change. What changed is the federal government's stated view of how it interacts with state abortion restrictions. Private litigation continues: in Idaho, a federal court's March 2025 preliminary injunction bars the state from enforcing its abortion ban against one hospital system's EMTALA-required care while that case proceeds (St. Luke's Health System v. Labrador, D. Idaho; case summary, a secondary source).

Michigan's situation differs from Idaho's or Texas's. Since December 2022 the Michigan Constitution has protected a "fundamental right to reproductive freedom" that includes abortion care and miscarriage management (Mich. Const. art. I, §28), so the direct conflict between EMTALA and a state ban doesn't arise for MI-4's hospitals in the same way. The federal question still matters to a member of Congress, because Congress wrote EMTALA and is the body that can clarify it. When emergency physicians believe ending a pregnancy is necessary to stabilize a patient, and a state restricts that treatment, what should federal law require?

Huizenga's general position on abortion is public. He called the Dobbs decision one that "correctly restores power usurped by the courts to the states and the representatives elected by the people" (June 24, 2022). The record reviewed for this page did not identify a public Huizenga position on what EMTALA requires in pregnancy emergencies, on the 2022 guidance, or on its rescission. As with the hospital rule, the absence of a statement doesn't establish a position.

The ACA deserves scrutiny, and the case against it isn't imaginary. Premiums and deductibles remain high. Provider consolidation has weakened competition in many markets. Prescription drugs remain expensive. The subsidies cost taxpayers hundreds of billions of dollars, and Medicaid has real financing and program-integrity problems. The ACA didn't solve American healthcare.

• Legislation Huizenga sponsors or cosponsors on insurance coverage and premium affordability, including any proposal to replace or supplement ACA coverage mechanisms, and any movement on the Community Multi-Share Coverage Program Act.
• Votes on the premium tax credit, cost-sharing reductions, and other Marketplace changes, including any Senate action on H.R. 1834 or H.R. 6703.
• Medicaid legislation, and what actually happens in Michigan once Healthy Michigan Plan work requirements and six-month renewals begin in 2027.
• Health-center and National Health Service Corps funding, which P.L. 119-75 extends only through Dec. 31, 2026, and Medicare telehealth flexibilities, which run through Dec. 31, 2027.
• Drug-pricing, PBM, provider-consolidation, price-transparency, and rural-health legislation.
• Whether CMS finalizes the hospital condition of participation, how the states' lawsuit over the funding rule is resolved, and any statement or oversight from Huizenga on CMS using Medicare and Medicaid participation or funding to restrict treatments.
• His position, if he states one, on EMTALA and emergency pregnancy care.

The test isn't whether Huizenga supports the Affordable Care Act. It's whether the healthcare policies he supports add up to a coherent, durable answer on coverage, affordability, access, and the proper limits of federal authority.